LEVICK | December 21st, 2020
Pharma’s Post-Pandemic Policy Outlook

To help prepare pharmaceutical industry public affairs professionals for what 2021 will bring, Delve will be launching a trends report in January focused on the political and reputational risks facing the industry.
Here’s what you need to know…
As the first COVID-19 vaccines were delivered this week, pharmaceutical industry leaders recognize that there are still many challenges ahead. While the industry overcame the herculean task of developing and distributing a vaccine in unprecedented time, the pandemic has brought previously obscure issues such as international patent rights and the global supply chain of pharmaceutical ingredients to the forefront of major public policy debates worldwide. With this heightened scrutiny and increased pressure from policymakers and the public, the pharmaceutical industry will have to continue to navigate these debates in 2021 and beyond.
To help prepare pharmaceutical industry public affairs professionals for what 2021 will bring, we will be launching a new occasional trends report in January focused on the political and reputational risks facing the industry. Below is a preview of some of the issues the trends report will cover, and we hope you will sign up to receive full editions of the report when they are published.
Cross-partisan pressure and scrutiny on drug prices will continue in the Biden era
Prior to the pandemic, policy makers on both sides of the isle debated how to address what many perceive as the high price of pharmaceuticals. While in most areas the Biden administration is likely to divert from President Trump’s policy direction, in this debate there may be more continuity than conflict. In September of this year President Trump signed an executive order to let Medicare negotiate drug prices through a Most Favored Nation (MFN) drug pricing policy. MFN policies use an international reference pricing model, tying prescription drug prices covered by Medicare Part B to the price paid by countries overseas. While this will likely end up being challenged in court, it likely will not deter the incoming Biden administration from seeking to advance a similar approach to reduce drug prices, which was also included in the House Democrats’ drug pricing plan endorsed by progressive groups.
Beyond this specific proposal, pharmaceutical companies can expect more scrutiny from Washington. President-elect Joe Biden’s pick to lead Health and Human Services (HHS), California Attorney General Xavier Becerra has been active in suing drug companies and confronting drug companies over the price of prescription drugs. In addition, Congress is likely to continue oversight hearings similar to those seen earlier this year and in prior years seeking to question the industry’s practices and pricing with encouragement from outside advocacy groups that have for years pushed for pricing transparency and reform at the local, state and federal levels.
The pandemic has globalized the fight over patent rights as activists seek to upend the industry
As the industry’s search for COVID-19 cures and treatments began in earnest, a People’s Vaccine movement emerged to demand any vaccine be made a “global public good” available for free and equitably distributed to both the developing and developed world simultaneously. This movement didn’t crop up overnight. For years, activists and groups advancing this campaign have been involved in fights across the developing world advocating for compulsory licensing laws to increase access to medicines. The People’s Vaccine movement has culminated with a fierce campaign advocating for World Trade Organization member states to back a proposal by India and South Africa for a waiver on intellectual property related to COVID-19 and calling for wealthy countries and pharmaceutical companies to back international intellectual property pools. This proposal remains under consideration and the debate over it will continue into 2021.
This movement to challenge patent rights has been building for a long time in the developing world, typically focused on specific regions and access to drugs that treat HIV/AIDS, Hepatitis, Tuberculosis, and other illnesses where advances in medical technology have not always been widely available in low and middle income countries. However, COVID has allowed this movement to become more global in its focus as it seeks to leverage the pandemic to reshape the model of how we fund and commercialize health technology. As one prominent activist in that movement, Medicines Law & Policy Director Ellen ‘t Hoen, recently stated, “We should not lose sight of the need to work to increase access to other new essential medicines. … After COVID, I believe cancer will prove to be the next big challenge,” with treatments “priced well beyond the ability to pay for most people and communities in the developing world.”
2020 brought heightened scrutiny on drug supply chains. 2021 could bring action to force them home.
As we wrote this past spring, the pandemic “exposed cracks in the worldwide supply chain for pharmaceuticals and medical supplies necessary to create and administer vaccines.” In hopes of addressing this, President-elect Biden has made clear that one of the goals of his administration will be to bring pharmaceutical supply chains and manufacturing back to the United States. On the campaign trail, Biden endorsed the creation of a national “Critical Drugs List” as part of an overarching plan to address supply chains shortages and encourage US-based manufacturing of prescription drugs.
Meanwhile, Congressional Republicans have joined bipartisan calls to spur greater U.S. drug manufacturing. This shift in approach by many free market-oriented Republicans stems from growing voter concerns regarding globalization as well as the national security threats associated with reliance on China – both of which have been exacerbated by COVID-19. However, the price tag that comes attached to bringing these supply chains and manufacturing abilities back to the United States has some industry leaders concerned, with one leader saying that it is “unrealistic” to think that it could be done in part to due to steep regulatory hurdles, while others argue government most put dollars behind their demands to bring drug manufacturing home.
Stay Ahead with Actionable Insights
As 2020 comes to a close and we approach the inauguration of new administration, the challenges the pharmaceutical industry will face in the year(s) ahead have come to the forefront of the public policy debate. Our team of analysts will continue to dig deeper and monitor developments that will impact the industry. Sign up for our trends report to keep you ahead of the curve, and feel free to reach out for more in-depth analysis on any or all of these challenges and opportunities facing the industry.
LEVICK | December 21st, 2020
Pharma’s Post-Pandemic Policy Outlook

To help prepare pharmaceutical industry public affairs professionals for what 2021 will bring, Delve will be launching a trends report in January focused on the political and reputational risks facing the industry.
Here’s what you need to know…
As the first COVID-19 vaccines were delivered this week, pharmaceutical industry leaders recognize that there are still many challenges ahead. While the industry overcame the herculean task of developing and distributing a vaccine in unprecedented time, the pandemic has brought previously obscure issues such as international patent rights and the global supply chain of pharmaceutical ingredients to the forefront of major public policy debates worldwide. With this heightened scrutiny and increased pressure from policymakers and the public, the pharmaceutical industry will have to continue to navigate these debates in 2021 and beyond.
To help prepare pharmaceutical industry public affairs professionals for what 2021 will bring, we will be launching a new occasional trends report in January focused on the political and reputational risks facing the industry. Below is a preview of some of the issues the trends report will cover, and we hope you will sign up to receive full editions of the report when they are published.
Cross-partisan pressure and scrutiny on drug prices will continue in the Biden era
Prior to the pandemic, policy makers on both sides of the isle debated how to address what many perceive as the high price of pharmaceuticals. While in most areas the Biden administration is likely to divert from President Trump’s policy direction, in this debate there may be more continuity than conflict. In September of this year President Trump signed an executive order to let Medicare negotiate drug prices through a Most Favored Nation (MFN) drug pricing policy. MFN policies use an international reference pricing model, tying prescription drug prices covered by Medicare Part B to the price paid by countries overseas. While this will likely end up being challenged in court, it likely will not deter the incoming Biden administration from seeking to advance a similar approach to reduce drug prices, which was also included in the House Democrats’ drug pricing plan endorsed by progressive groups.
Beyond this specific proposal, pharmaceutical companies can expect more scrutiny from Washington. President-elect Joe Biden’s pick to lead Health and Human Services (HHS), California Attorney General Xavier Becerra has been active in suing drug companies and confronting drug companies over the price of prescription drugs. In addition, Congress is likely to continue oversight hearings similar to those seen earlier this year and in prior years seeking to question the industry’s practices and pricing with encouragement from outside advocacy groups that have for years pushed for pricing transparency and reform at the local, state and federal levels.
The pandemic has globalized the fight over patent rights as activists seek to upend the industry
As the industry’s search for COVID-19 cures and treatments began in earnest, a People’s Vaccine movement emerged to demand any vaccine be made a “global public good” available for free and equitably distributed to both the developing and developed world simultaneously. This movement didn’t crop up overnight. For years, activists and groups advancing this campaign have been involved in fights across the developing world advocating for compulsory licensing laws to increase access to medicines. The People’s Vaccine movement has culminated with a fierce campaign advocating for World Trade Organization member states to back a proposal by India and South Africa for a waiver on intellectual property related to COVID-19 and calling for wealthy countries and pharmaceutical companies to back international intellectual property pools. This proposal remains under consideration and the debate over it will continue into 2021.
This movement to challenge patent rights has been building for a long time in the developing world, typically focused on specific regions and access to drugs that treat HIV/AIDS, Hepatitis, Tuberculosis, and other illnesses where advances in medical technology have not always been widely available in low and middle income countries. However, COVID has allowed this movement to become more global in its focus as it seeks to leverage the pandemic to reshape the model of how we fund and commercialize health technology. As one prominent activist in that movement, Medicines Law & Policy Director Ellen ‘t Hoen, recently stated, “We should not lose sight of the need to work to increase access to other new essential medicines. … After COVID, I believe cancer will prove to be the next big challenge,” with treatments “priced well beyond the ability to pay for most people and communities in the developing world.”
2020 brought heightened scrutiny on drug supply chains. 2021 could bring action to force them home.
As we wrote this past spring, the pandemic “exposed cracks in the worldwide supply chain for pharmaceuticals and medical supplies necessary to create and administer vaccines.” In hopes of addressing this, President-elect Biden has made clear that one of the goals of his administration will be to bring pharmaceutical supply chains and manufacturing back to the United States. On the campaign trail, Biden endorsed the creation of a national “Critical Drugs List” as part of an overarching plan to address supply chains shortages and encourage US-based manufacturing of prescription drugs.
Meanwhile, Congressional Republicans have joined bipartisan calls to spur greater U.S. drug manufacturing. This shift in approach by many free market-oriented Republicans stems from growing voter concerns regarding globalization as well as the national security threats associated with reliance on China – both of which have been exacerbated by COVID-19. However, the price tag that comes attached to bringing these supply chains and manufacturing abilities back to the United States has some industry leaders concerned, with one leader saying that it is “unrealistic” to think that it could be done in part to due to steep regulatory hurdles, while others argue government most put dollars behind their demands to bring drug manufacturing home.
Stay Ahead with Actionable Insights
As 2020 comes to a close and we approach the inauguration of new administration, the challenges the pharmaceutical industry will face in the year(s) ahead have come to the forefront of the public policy debate. Our team of analysts will continue to dig deeper and monitor developments that will impact the industry. Sign up for our trends report to keep you ahead of the curve, and feel free to reach out for more in-depth analysis on any or all of these challenges and opportunities facing the industry.
- Brand
- Corporate Revolt Over Campaign Donations Shakes Political World
- What Happens Next?
- CSR & Sustainability
- Public Perception & the Biden Transition
- WATCH: Reputation Management with PRSA
- Over the River and Through The Woods
- Why Non-Profits are so Vulnerable to Crisis Risk
- The Threat to Free Markets
- What Happens When Nonprofits Get Caught In The Klieg Lights?
- You Took a PPP Loan. Now Get Ready to Talk About It.
- Avoid Future Shock: 10 Changes to Anticipate for 2021
- Guidance for Corporate Reputation Risk
- Communications
- What Happens Next?
- CSR & Sustainability
- A Conversation with Abbe Lowell
- A New Year’s Resolution
- Public Perception & the Biden Transition
- WATCH: Reputation Management with PRSA
- Leveraging Legal Expertise in Communications
- Over the River and Through The Woods
- Why Non-Profits are so Vulnerable to Crisis Risk
- The Threat to Free Markets
- Dropping the Mic
- Combatting Misinformation
- Company News
- Recent Awards & Recognition
- Won’t You Be My Neighbor?
- What’s a Director to Do?
- LEVICK Announces Partnership with BCG
- A New Look
- Albert Krieger, 1923-2020
- LEVICK Announces Partnership with Jipyong
- Speaking to In-House Counsel
- Childhood Lessons
- LEVICK Announces New Webinar Series with Turbine Labs
- LEVICK Launches New Website
- LEVICK to Launch Podcast
- Crisis
- How to Stop the Madness
- Corporate Revolt Over Campaign Donations Shakes Political World
- A Remembrance of Tommy Raskin
- No ‘justice’ in rep’s vote
- A Call for Orderly & Peaceful Transition of Power
- Recovering from the Greatest Sacrifice
- The Cost of Government Regulation and the Threat to Free Enterprise
- What Happens Next?
- A Conversation with Abbe Lowell
- Covid-19: The Pandemic that Never Should Have Happened
- Public Perception & the Biden Transition
- WATCH: Reputation Management with PRSA
- Finance
- The Threat to Free Markets
- Advisory & Insurance Services
- WATCH: Revolutionizing Litigation Finance
- Litigation Finance: Revolutionizing Litigation
- Consumer-Focused Solutions for Financial Health
- Event: Consumer-Focused Solutions for Financial Health
- Sports: Power and Money in a New Age of Social Justice
- The Balancing Act: The Role of Whistleblowers in American Commerce and Government
- The Evolving and More Powerful FARA
- FCPA & Compliance in a Time of Uncertainty
- Shareholders vs. Stakeholders: Is the Paradigm Shifting?
- CommPRO: Transparent Political Donations
- Guest Column
- Guest Blog: The Mainstream Media Gets an A for Intellectual Arrogance, an F for Journalism
- Buckle up Directors: Cybersecurity Risk and Bankruptcy Risk Are Not Mutually Exclusive
- Buckle up Directors: Cybersecurity Risk and Bankruptcy Risk Are Not Mutually Exclusive
- South Africa: The Slow Decline of the ANC
- Why CSR Fails and How to Fix It
- What to Expect Following the European Elections?
- Buhari Inaugurated. What Now for Nigeria?
- Marketing- It’s Up To You…
- Crisis Management lessons from the air-crash investigation model
- The Future of War
- Health
- Food Issues & the Biden Administration
- Covid-19: The Pandemic that Never Should Have Happened
- Pharma’s Post-Pandemic Policy Outlook
- Keeping Hope Alive
- Real Herd Immunity
- The Fiction of College Sports Amateurism
- Mac Summit: Crisis Communications in a Post-Covid, Post-Election World
- Travel Industry Communications in the Age of Covid-19
- Track of Time
- Is C-19 Taking Women Lawyers’ Careers Back to the 1950s?
- Post-Pandemic PR Strategy
- Bankruptcy: A Culture of Transparency
- In Memoriam
- Snider’s Super Foods: Locally World Famous
- Speak Truth With Love, Not Anger
- In Memoriam: Stephen Susman
- Letter to the Movement
- John Lewis’ Life Bridged the Best of America
- Albert Krieger, 1923-2020
- In Memoriam of Marcia Horowitz
- Jim Lehrer Passes Away
- Martin Luther King, Jr.
- Harold Burson Passes Away
- Interviews
- CommPRO: Ruth Bader Ginsberg’s Life & Legacy
- Richard Levick on “My Wakeup Call”
- Primerus Webinar: Into the Wind
- The Future of Baseball Post-Pandemic
- Webinar: The End of Brand Neutrality
- Thought Leadership & Organic Growth
- Man & Superman
- LEVICK Announces New Webinar Series with Turbine Labs
- Navigating Coronavirus Challenges in the Insurance Industry
- VIDEO: How to Anticipate & Avoid a Crisis
- What’s Next? with Julie Chase
- What’s Next?: California Electoral Behavior
- Law Firms
- You Took a PPP Loan. Now Get Ready to Talk About It.
- Beyond Black Swan: Positioning the law firm for the new normal
- A Salute to Personal Courage and the Rule of Law
- Cyber Risk Institute Expands Its Profile
- When a client becomes a law firm’s PR nightmare
- The General Counsel’s Dilemma
- A First Look at the Google Antitrust Suit
- The Latest Top Class Actions
- Trust on Trial: How Communicators Succeed in a World No Longer Trusted
- The Latest Settlements, Class actions, Investigations & More
- Managing Legal & Communication Advice in a Crisis
- Class Action Lawsuits 2020
- Litigation
- A Conversation with Abbe Lowell
- Leveraging Legal Expertise in Communications
- You Took a PPP Loan. Now Get Ready to Talk About It.
- Beyond Black Swan: Positioning the law firm for the new normal
- A Salute to Personal Courage and the Rule of Law
- Cyber Risk Institute Expands Its Profile
- When a client becomes a law firm’s PR nightmare
- The General Counsel’s Dilemma
- WATCH: Revolutionizing Litigation Finance
- Litigation Finance: Revolutionizing Litigation
- A First Look at the Google Antitrust Suit
- The Latest Top Class Actions
- Our Work
- Recent Awards & Recognition
- The Cyber Bad Guys Are Getting Worse
- Crisis Communications & The Age of Cancel Culture
- Standing on the Shoulders of Giants
- Video: Conversations with American Legends
- Staying Ahead of the Crisis
- A New Era of Insurance Marketing
- Infographic: Judgment Free Zone
- Infographic: Barriers to Entry
- Infographic: History Meter
- Assistance for Law Firms Engaged in Pro Bono
- Webinar: The End of Brand Neutrality
- Public Affairs
- How to Stop the Madness
- Corporate Revolt Over Campaign Donations Shakes Political World
- No ‘justice’ in rep’s vote
- A Call for Orderly & Peaceful Transition of Power
- Recovering from the Greatest Sacrifice
- Food Issues & the Biden Administration
- The Cost of Government Regulation and the Threat to Free Enterprise
- What Happens Next?
- CSR & Sustainability
- A Conversation with Abbe Lowell
- Public Perception & the Biden Transition
- You Took a PPP Loan. Now Get Ready to Talk About It.
- Risk
- Ingredients of Decency
- ESG Performance and Credit Markets
- The Coronavirus Saga is Just Beginning
- No. 1 Risk of the Decade
- The Risk Evolution of Corporate Risk
- Extend Risk Management Reach
- Collective Action
- Risk Identifying Software
- The New Risk of Doing Nothing
- Political Unrest In Hong Kong
- High-Profile Kidnaps in African National Parks
- Cyber Resilience
- Social
- How to Stop the Madness
- A Remembrance of Tommy Raskin
- No ‘justice’ in rep’s vote
- A Call for Orderly & Peaceful Transition of Power
- Recovering from the Greatest Sacrifice
- CSR & Sustainability
- A New Year’s Resolution
- Dropping the Mic
- Won’t You Be My Neighbor?
- Crisis, Covid, DEI & the Election
- MLK’s Memphis Address
- The Fiction of College Sports Amateurism
- Technology
- Constella Intelligence Announces Hunter for Improved Investigation Capability
- Cyber Risk Institute Expands Its Profile
- Digital Politics: The Future of Voting Technology
- Ethics in Electronics
- The Cyber Bad Guys Are Getting Worse
- A First Look at the Google Antitrust Suit
- The Pause
- Cybersecurity Incidents of the Summer
- The Changing Digital Economy and Cyber Risks
- The Future of U.S. Manufacturing
- Tech CEO Summer Superbowl hearing
- Technology & Privacy Alert
- This Week
- A Remembrance of Tommy Raskin
- A New Year’s Resolution
- Over the River and Through The Woods
- Dropping the Mic
- Won’t You Be My Neighbor?
- The Cyber Bad Guys Are Getting Worse
- What We Hear
- Track of Time
- Video: Conversations with American Legends
- Conversations with American Legends
- A New Era of Insurance Marketing
- American Legend